← All trials
NCT01599923
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2005
- Primary completion
- Jun 1, 2006
- Completion date
- Aug 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 29
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Instituto BioclonLead sponsor
- Instituto BioclonStudy director
- Children's Hospital of MorelosOverall official - principal investigator
- University of ArizonaOverall official - principal investigator
- University of ArizonaCollaborator
- National Autonomous University of MexicoStudy chair
- National Autonomous University of MexicoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.